. Author manuscript; available in PMC: 2021 Jul 28.

Published in final edited form as: J Clin Pharmacol. 2019 Aug 29;60(2):264–273. doi: 10.1002/jcph.1522

Table 2.

Treatment-Emergent Adverse Events (TEAEs) During Study: Overall and Common

	BNZ-1 Dose Cohort (n = 3/Cohort)
	0.2 mg/kg	0.4 mg/kg	0.8 mg/kg	1.6 mg/kg	3.2 mg/kg	6.4 mg/kg	Overall
Total TEAEs observed	6	10	2	1	3	3	25
TEAE by severity
Mild	6	6	2	1	3	2	20 (80%)
Moderate	0	4	0	0	0	1	5 (20%)
Severe	0	0	0	0	0	0	0
Common TEAEs (> 1 subject overall)
Headache	1 (33%)	1 (33%)	0	1 (33%)	0	0	3 (17%)